Combinatorial RNA interference therapy prevents selection of pre-existing HBV variants in human liver chimeric mice

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Shih, Yao Ming ^a,b   Sun, Cheng Pu ^b   Chou, Hui Hsien ^c   Wu, Tzu Hui ^a   Chen, Chun Chi ^d   Wu, Ping Yi ^b   Enya Chen, Yu Chen ^b   Bissig, Karl Dimiter ^e   Tao, Mi Hua ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c Iowa State University   (United States)

^d INSTITUTE OF MICROBIOLOGY   (China)

^e CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULAR DNA; COMPLEMENTARY DNA; SMALL INTERFERING RNA; VIRUS DNA; VIRUS RNA;

ADMINISTRATION AND DOSAGE; ANIMAL; BIOLOGY; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETIC VARIATION; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HISTOCOMPATIBILITY; HUMAN; LIVER TRANSPLANTATION; MOUSE; MUTATION; PROCEDURES; RNA INTERFERENCE; TRANSGENIC MOUSE; VIROLOGY; VIRUS LOAD;

ANIMALS; COMPUTATIONAL BIOLOGY; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DNA, CIRCULAR; DNA, COMPLEMENTARY; DNA, VIRAL; GENETIC THERAPY; GENETIC VARIATION; GENETIC VECTORS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER TRANSPLANTATION; MICE; MICE, TRANSGENIC; MUTATION; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA, VIRAL; TRANSPLANTATION CHIMERA; VIRAL LOAD;

EID: 84944755206     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15259     Document Type: Article

References (51)

1. Iloeje, U. H., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 130, 678-686 (2006
2. Chen, C. J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 295, 65-73 (2006
3. Tseng, T. C., et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology. 57, 441-450 (2013
4. Yang, H. I., et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 347, 168-174 (2002
5. Scaglione, S. J., & Lok, A. S. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology. 142, 1360-1368 e1361 (2012
6. Chotiyaputta, W., & Lok, A. S. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol. 6, 453-462 (2009
7. Lee, Y. S., et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 43, 1385-1391 (2006
8. Villet, S., et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol. 48, 747-755 (2008
9. Warner, N., & Locarnini, S. The antiviral drug selected hepatitis B virus rtA181T/sW172 mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology. 48, 88-98 (2008
10. Wu, L., & Belasco, J. G. Let me count the ways: mechanisms of gene regulation by miRNAs and siRNAs. Mol Cell. 29, 1-7 (2008
11. McCaffrey, A. P., et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol. 21, 639-644 (2003
12. Chen, C. C., et al. Long-Term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-Associated virus. 8-delivered short hairpin RNA. Gene Ther. 14, 11-19 (2007
13. Wooddell, C. I., et al. Hepatocyte-Targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection. Mol Ther. 21, 973-985 (2013
14. Reignat, S., et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med. 195, 1089-1101 (2002
15. Chen, M. T., et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci USA. 101, 14913-14918 (2004
16. Sun, C. P., et al. Studies of efficacy and liver toxicity related to adeno-Associated virus-mediated RNA interference. Hum Gene Ther. 24, 739-750 (2013
17. Chen, C. C., et al. Comparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-Associated virus serotypes. 7, 8, and 9. Mol Ther. 17, 352-359 (2009
18. Chen, C. C., et al. Use of RNA interference to modulate liver adenoma development in a murine model transgenic for hepatitis B virus. Gene Ther. 19, 25-33 (2012
19. Boden, D., Pusch, O., Lee, F., Tucker, L., & Ramratnam, B. Human immunodeficiency virus type 1 escape from RNA interference. J Virol. 77, 11531-11535 (2003
20. Gitlin, L., Stone, J. K., & Andino, R. Poliovirus escape from RNA interference: short interfering RNA-Target recognition and implications for therapeutic approaches. J Virol. 79, 1027-1035 (2005
21. Kapadia, S. B., Brideau-Andersen, A., & Chisari, F. V. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA. 100, 2014-2018 (2003
22. Wu, H. L., et al. RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology. 128, 708-716 (2005
23. ter Brake, O., Konstantinova, P., Ceylan, M., & Berkhout, B. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther. 14, 883-892 (2006
24. Chandra, P. K., et al. Inhibition of Hepatitis C Virus Replication by Intracellular Delivery of Multiple siRNAs by Nanosomes. Mol Ther. 20, 1724-1736 (2012
25. Weinberg, M. S., et al. Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. Mol Ther. 15, 534-541 (2007
26. Reynolds, A., et al. Rational siRNA design for RNA interference. Nat Biotechnol. 22, 326-330 (2004
27. Grimm, D., et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 441, 537-541 (2006
28. Chou, H. H., Hsia, A. P., Mooney, D. L., & Schnable, P. S. Picky: oligo microarray design for large genomes. Bioinformatics. 20, 2893-2902 (2004
29. Chen, X., Liu, P., & Chou, H. H. Whole-genome thermodynamic analysis reduces siRNA off-Target effects. PLoS One. 8, e58326 (2013
30. Guidotti, L. G., et al. Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci USA. 93, 4589-4594 (1996
31. Bissig, K. D., et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest. 120, 924-930 (2010
32. Dandri, M., et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology. 33, 981-988 (2001
33. Sugiyama, M., et al. Early dynamics of hepatitis B virus in chimeric mice carrying human hepatocytes monoinfected or coinfected with genotype G. Hepatology. 45, 929-937 (2007
34. Lisowski, L., et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature. 506, 382-386 (2014
35. Yim, H. J., et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 44, 703-712 (2006
36. Rodriguez, C., Chevaliez, S., Bensadoun, P., & Pawlotsky, J. M. Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology. 58, 890-901 (2013
37. Zhu, Y., et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol. 75, 311-322 (2001
38. Addison, W. R., et al. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol. 76, 6356-6363 (2002
39. Yang, H. C., & Kao, J. H. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. Emerg Microbes Infect. 3, e64 (2014
40. Suhy, D. A., et al. Safe, long-Term hepatic expression of anti-HCV shRNA in a nonhuman primate model. Mol Ther. 20, 1737-1749 (2012
41. Ely, A., Naidoo, T., & Arbuthnot, P. Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles. Nucleic Acids Res. 37, e91 (2009
42. Bissig, K. D., Le, T. T., Woods, N. B., & Verma, I. M. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc Natl Acad Sci USA. 104, 20507-20511 (2007
43. Azuma, H., et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol. 25, 903-910 (2007
44. Chou, Y. C., et al. Evaluation of transcriptional efficiency of hepatitis B virus covalently closed circular DNA by reverse transcription-PCR combined with the restriction enzyme digestion method. J Virol. 79, 1813-1823 (2005
45. Xiao, X., Li, J., & Samulski, R. J. Production of high-Titer recombinant adeno-Associated virus vectors in the absence of helper adenovirus. J Virol. 72, 2224-2232 (1998
46. Yang, P. L., Althage, A., Chung, J., & Chisari, F. V. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA. 99, 13825-13830 (2002
47. Werle, E., Schneider, C., Renner, M., Volker, M., & Fiehn, W. Convenient single-step, one tube purification of PCR products for direct sequencing. Nucleic Acids Res. 22, 4354-4355 (1994
48. Allen, M. I., et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol. 37, 3338-3347 (1999
49. Zhang, Y. Y., & Summers, J. Low dynamic state of viral competition in a chronic avian hepadnavirus infection. J Virol. 74, 5257-5265 (2000
50. Werle-Lapostolle, B., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 126, 1750-1758 (2004
51. Seeger, C., & Sohn, J. A. Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic Acids. 3, e216 (2014